BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36809990)

  • 1. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.
    De Castro J; Insa A; Collado-Borrell R; Escudero-Vilaplana V; Martínez A; Fernandez E; Sullivan I; Arrabal N; Carcedo D; Manzaneque A
    BMC Pulm Med; 2023 Feb; 23(1):69. PubMed ID: 36809990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Burden of Recurrence in Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer: A Retrospective Study Using Nationwide Claims Data of South Korea.
    Byun JY; Lee JE; Shim YB; Kim J; Lee SY; Shin BR; Yoon NR; Park MH; Lee EK
    Adv Ther; 2023 Feb; 40(2):550-567. PubMed ID: 36404368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs.
    Apple J; DerSarkissian M; Shah A; Chang R; Chen Y; He X; Chun J
    J Comp Eff Res; 2023 Nov; 12(11):e230107. PubMed ID: 37655686
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic burden of breast cancer in northern Serbia.
    Milovic M; Tamas T; Crnobrnja V; Paut Kusturica M
    Front Public Health; 2023; 11():1265301. PubMed ID: 38162600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico.
    Arrieta O; Quintana-Carrillo RH; Ahumada-Curiel G; Corona-Cruz JF; Correa-Acevedo E; Zinser-Sierra J; de la Mata-Moya D; Mohar-Betancourt A; Morales-Oyarvide V; Reynales-Shigematsu LM
    Tob Induc Dis; 2014; 12(1):25. PubMed ID: 25653577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic assessment of NGS testing workflow for NSCLC in a healthcare setting.
    Seminati D; L'Imperio V; Casati G; Ceku J; Pilla D; Scalia CR; Gragnano G; Pepe F; Pisapia P; Sala L; Cortinovis DL; Bono F; Malapelle U; Troncone G; Novello S; Pagni F
    Heliyon; 2024 Apr; 10(7):e29272. PubMed ID: 38617925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of non-small cell lung cancer metastases in TRACERx.
    Al Bakir M; Huebner A; Martínez-Ruiz C; Grigoriadis K; Watkins TBK; Pich O; Moore DA; Veeriah S; Ward S; Laycock J; Johnson D; Rowan A; Razaq M; Akther M; Naceur-Lombardelli C; Prymas P; Toncheva A; Hessey S; Dietzen M; Colliver E; Frankell AM; Bunkum A; Lim EL; Karasaki T; Abbosh C; Hiley CT; Hill MS; Cook DE; Wilson GA; Salgado R; Nye E; Stone RK; Fennell DA; Price G; Kerr KM; Naidu B; Middleton G; Summers Y; Lindsay CR; Blackhall FH; Cave J; Blyth KG; Nair A; Ahmed A; Taylor MN; Procter AJ; Falzon M; Lawrence D; Navani N; Thakrar RM; Janes SM; Papadatos-Pastos D; Forster MD; Lee SM; Ahmad T; Quezada SA; Peggs KS; Van Loo P; Dive C; Hackshaw A; Birkbak NJ; Zaccaria S; ; Jamal-Hanjani M; McGranahan N; Swanton C
    Nature; 2023 Apr; 616(7957):534-542. PubMed ID: 37046095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine.
    Graham DM; Leighl NB
    Front Oncol; 2014; 4():258. PubMed ID: 25295228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct and indirect economic burden of lung cancer in Denmark a nationwide study.
    Gouliaev A; Risikesan J; Christensen NL; Rasmussen TR; Hilberg O; Ibsen R; Løkke A
    Eur Clin Respir J; 2021; 8(1):1951963. PubMed ID: 34377377
    [No Abstract]   [Full Text] [Related]  

  • 10. First recurrence of small cell lung cancer presenting as subacute monoarticular arthritis.
    McCormick JP; Trueick R; Connaughton J; McDonnell N
    BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34417237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and treatment of early-stage non-small-cell lung cancer: the Value-Based Healthcare approach to address social disparities.
    Marzorati C; Masiero M; Pravettoni G
    Future Oncol; 2024 Apr; ():1-4. PubMed ID: 38660980
    [No Abstract]   [Full Text] [Related]  

  • 12. AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013.
    Harbeck N; Scharl A; Thomssen C; Müller V
    Breast Care (Basel); 2013 Jun; 8(3):181-5. PubMed ID: 24415967
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective.
    Yip CY; Greystoke A; Abogunrin S; Belleli R; Di Maio D; Rouse P; Jovanoski N
    Lung Cancer; 2023 May; 179():107171. PubMed ID: 36947997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer.
    Riano I; Abuali I; Sharma A; Durant J; Dragnev KH
    Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and medical costs of non-small cell lung cancer patients according to the first-line treatment: An observational study using the Kyoto City Integrated Database.
    Shimamoto T; Tateyama Y; Kobayashi D; Yamamoto K; Takahashi Y; Ueshima H; Sasaki K; Nakayama T; Iwami T
    Thorac Cancer; 2023 Jun; 14(17):1574-1580. PubMed ID: 37082875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.
    Das M; Ogale S; Jovanoski N; Johnson A; Nguyen C; Bhagwakar J; Lee JS
    Immunotherapy; 2023 Jun; 15(8):573-581. PubMed ID: 37021770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.
    Meunier A; Longworth L; Gomes M; Ramagopalan S; Garrison LP; Popat S
    Pharmacoeconomics; 2023 Aug; 41(8):1011-1025. PubMed ID: 37296369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
    Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL
    Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
    Parekh J; Parikh K; Reuss JE; Friedlaender A; Addeo A
    Curr Oncol Rep; 2023 Aug; 25(8):913-922. PubMed ID: 37249833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients.
    Linardou H; Lampaki S; Koliou GA; Vozikis A; Boutis A; Nikolaidi A; Kontogiorgos I; Papakotoulas P; Christopoulou A; Spyratos D; Bafaloukos D; Psyrri A; Grivas A; Koumarianou A; Tsiakitzis K; Mauri D; Rigakos G; Aravantinos G; Papantoniou P; Oikonomopoulos G; Fountzilas E; Koufaki MI; Kaparelou M; Liolis E; Mountzios G; Kosmidis P; Fountzilas G; Samantas E
    Anticancer Res; 2023 Jun; 43(6):2799-2812. PubMed ID: 37247889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.